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fractions against 69.1 Gy/32 fractions in the IMRT group. 
Endpoints were local control, acute and late toxicity.  
Results A. Interim analysis (n = 150) showed low rates of 
moist desquamation, mostly located in the infra-mammary 
fold (5/75 WBI-SeqB vs 3/75 WBI-TDP-SIB, p =0.5). Trends in 
favor of WBI-TDP-SIB were observed for breast edema 
(p=0.08) and pruritus (p = 0.1). B. The volume of normal 
tissue receiving 4 Gy, 6 Gy and 8 Gy was at least 3, 6 and 13 
times smaller in the DP-8Gy arm compared to Conv-8Gy and 
DP-16Gy (p<0.05). DP-8Gy resulted in a pain response of 80% 
compared to 53% and 60% for Conv-8Gy and DP-16Gy. Quality 
of life analysis suggests better outcome for patients treated 
in the DP-8Gy arm with the scores ‘painful characteristic’, 
‘insomnia’ and ‘appetite loss’ reaching significance (p<0.05). 
C. Local control at 5 y was 83.4% and 75.2% in the DP- and 
IMRT-treated patients, respectively (p=0.28). Grades of acute 
dysphagia and mucositis were higher for the DP- than for the 
IMRT-treated group (p=0.03 and p=0.08, respectively) but 
differed according to DP-technique and –prescription. Poorly 
healing mucosal ulcers at the locations of the highest doses 
were observed in 9 DP- and 3 IMRT-treated patients (p=0.07) 
and reflect dose-limiting toxicity (DLT). Analysis of all DP-
treated patients showed that DP-planning using a linear 
relation between 18F-FDG voxel-intensity and dose was 
associated with high risk of DLT if peak-doses were >84 Gy or 
the volume receiving >80 Gy was >1.75 cc in 30-fraction 
schedules (OTT = 6 weeks). Discussion and conclusions  
The term DP covers a variety of techniques that open a vast 
spectrum of applications.The use of TDP after breast-
conserving surgery allows to integrate boost treatment in WBI 
without increasing toxicity. In bone metastasis, DP-8Gy was 
selected as a candidate experimental arm to test the 
hypothesis of improved palliation by reducing the irradiated 
volume. A confirmatory phase III trial is underway. In loco-
regionally advanced head&neck cancer, DP may open a 
window for improving local control. However, the safety 
margin for dose-escalation is narrow. Poorly healing mucosal 
ulcers at the peak-dose regions are DLT of DP. The 
dose/volume/DLT relationship casts doubt on the safety of 
linear 18F-FDG voxel-intensity based DP. A phase III trial 
using non-linear DP is underway. Tumor heterogeneity –
known for decades- supports DP and refutes the use of 
homogeneous dose distributions. Dose escalation to 
radioresistant regions in the tumor or decreasing the 
irradiated volume may be a conceptually naive way to use 
DP. The insight that ionizing radiation can enhance vascular 
and immunogenic mechanisms of cell death opens a new field 
for DP characterized by large fraction doses to small sub-
volumes of tumor. In these applications, direct cancer cell 
kill might be subordinate to other goals of DP including 
amplifying bystander and abscopal effects or breaking 
immune tolerance. Combination of DP with 
immunomodulating drugs or drugs that target vasculature or 
immune checkpoints are investigated to validate these 
concepts. 
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Any additional dose that can be applied without harm will lift 
tumour control in a patient population. Dose painting (DP) 
claims to make better use of dose than an indiscriminate or 
random escalation: by virtue of functional imaging, it should 
be more effective, more selective and more patient-specific. 
Still, on a pragmatic level, DP can often be summarized by 
“we boost because we can”. What does it take to go more 
biological?  
Obstacles lie in quantitative functional image acquisition, 
image interpretation, dose prescription and collection of 
evidence. Unfortunately, quantitative functional imaging is 
notoriously capricious. The problems tend to grow the more 
specific in terms of tumour biology an imaging modality is - 
which is one of the reasons for the popularity of FDG-PET, 
being arguably one of the least specific modalities. A specific 
modality may be more intriguing scientifically, but obviously 
shows only a narrow aspect of tumour biology, which may 
create a need for a combination of multiple modalities. 
Imaging modalities usually operate at length scales far 
greater than the phenomena to which they are sensitive. This 
can make the interpretation of images challenging, especially 
when tracer kinetics need to be considered. Imaging 
sophistication alone reveals little of the import of some 
physiological or biological trait for treatment outcome. Only 
clinical data can fill this gap in biological understanding with 
some confidence. Further, a single image is just a snapshot of 
a dynamically evolving tumour, and if taken pre-treatment, 
says little about the tumour´s response to therapy. 
Therefore, without any highly suggestive clinical evidence, 
the prospects for naive (i.e. model-based) DP are bleak.  
Accordingly, the majority of DP trials to date are pragmatic 
in their choice of imaging modality and –protocol, and dose 
prescription. In addition to being practical, especially in a 
multi-centric setting, this also ensures that a proof of benefit 
(of both boosting and imaging) can eventually be made. The 
essential advantage of “we boost because we can” over 
sophisticated “dose painting by numbers” is, that it 
generates the data needed to reach said sophistication.  
From this pragmatic standpoint, neither today´s imaging 
capabilities nor the understanding of their relevance to 
tumour treatment response are sufficient to speak of an 
established biological rationale for DP. Some clinical 
evidence exists in few instances that links certain functional 
imaging to lack of tumour control or even location of 
recurrence. Given this, workable DP concepts today are 
rather shaped by considerations about image sensitivity and 
specificity and organ mobility, than biology. 
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Purpose/Objectives: This work aims at formally identifying 
the methodological issues that hinder the implementation 
and adoption of dose painting (DP) in radiotherapy. DP entails 
the use of functional imaging to set up a non-uniform dose 
escalation, either with sub-contours or voxel-to-voxel 
variations. Although theoretically appealing, DP has not 
succeeded yet in passing from research to clinical use. This 
work reviews the physical, mathematical, and statistical 
causes of this delay, in the specific case of DP guided by PET.  
 
Method: The following steps occur in PET-based DP: 
acquisition of PET images (before and/or during treatment, 
with one or several tracers), conversion of the uptake(s) into 
a dose increment, treatment plan optimization, fractionated 
treatment delivery, accumulation and assessment of the 
delivered dose, and optional treatment adaptation. Every 
step or piece of data in this path can be modeled to 
investigate its shortcomings. All PET tracers are 
characterized with their specificity and sensitivity as a 
surrogate of some biological variable of interest in given 
conditions (e.g., before or during radiotherapy). PET images 
are described by their resolution and signal-to-noise ratio. 
Treatment plan quality is assessed by a quality-volume 
histogram (QVH), namely, a DP-specific dose-volume 
histogram that considers the ratio planned dose over 
prescribed dose. Random and systematic patient setup errors 
are quantified with their respective standard deviation. Non-
rigid registration of pre- and per-treatment images is used to 
approximate the cumulated dose, taking into account patient 
evolution (tumor regression, possible weight loss).  
 
Results: Our main result is the formal proof that PET-based 
DP cannot lead to a delivered dose that is strongly correlated 
with the tracer uptake at the microscopic level. This weak 
correlation is caused by: i) The limited information conveyed 
by heterogeneities observed in PET images. Current PET 
systems have a low resolution and a low signal-to-noise ratio, 
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which translate into biases and variance in the uptake 
measurement. Moreover, the tracer has typically a source-to-
background ratio that decreases during treatment (e.g. after 
3 weeks for FDG). This intrinsically limits the number of 
interpretable images that can be acquired during treatment. 
ii) Dose blurring due to treatment fractionation. Daily setup 
introduces geometrical errors. Random errors blur the 
planned dose, while systematic ones shift it. A systematic 
drift can also be caused patient evolution (tumor regression, 
weight loss), thus making adaptive radiotherapy a desirable 
prerequisite for DP. All this shows that DP must cope with 
limited information about the real uptake heterogeneities. If 
directly converted into a dose prescription, these blurred 
heterogeneities are likely to be further smoothed or even 
shifted by random and systematic errors if the delivered dose 
is considered. While dose blurring is beneficial to uniformity 
within the targets in usual treatment plans, it is actually 
detrimental to any form of intended heterogeneity. Dose 
blurring cannot be compensated for with usual safety 
margins, since they rely on a model that implicitly assumes 
dose uniformity and further reinforces it to guarantee 
coverage. Instead, robust plan optimization must be used, 
either by modeling the setup errors in the optimizer or by 
providing a modified prescription, dilated for systematic 
errors and deconvolved for random errors. It is however 
noteworthy that ensuring coverage might sound paradoxical 
in DP: it widens the dose peaks and increases the mean dose, 
whereas DP precisely aims at a selective and parsimonious 
escalation.  
 
Conclusions: Advanced treatment techniques such as 
intensity-modulated radiotherapy make DP technically 
feasible: a non-uniform dose prescription, with rather sharp 
gradients, can be accurately delivered at each fraction. 
Issues are located upstream (poor quality of PET images, 
which further decreases during treatment) and downstream 
(dose blurring due to setup errors and patient evolution). 
These issues lead to delivered doses that are weakly 
correlated to the underlying microscopic reality. To increase 
this correlation, an adaptive treatment strategy is a 
prerequisite to DP. Combined with other confounding factors, 
this weak correlation also jeopardizes the chances for an 
evidence-based approach to succeed in differentiating 
various flavors of DP from each other or from other 
comparable escalation strategies. 
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Since 2012 the Advisory committee for radiation oncology 
practice  ACROP has taken over the responsibility for the 
initiation and coordination of ESTRO internal guidelines ae 
well as multidisciplinary guidelines together with other 
scientific societies. 
During the ESTRO 35 ACROP session C Belka will present the 
workflow and SOP of ACROP, K Tanderup will give an brief 
overview of the ongoing and mature guidelines in the areas 
brachtherapy and physics and Max Niyazi will present the new 
guideline on Target volume delineation in Glioblastoma. 
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The ACROP committee has been established to generate 
European guidelines on radiotherapeutic topics and 
therefore, a group of thirteen experts had been selected to 
draft target delineation guidelines on glioblastoma. This talk 
will summarize the different steps that were taken to pull 
together all relevant information and will highlight the most 
relevant issues having been included within this guideline. In 
brief, treatment preparation, imaging prerequisites, 
delineation guidelines and pitfalls, planning objectives and 
normal tissue constraints will be discussed. The panel 
members have ensured to update this guidline within a 2 
year's time frame and updates will be given as amendments if 
there are scientific breakthroughs. 
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GEC ESTRO has a long term tradition for development and 
publication of guidelines within brachytherapy. These 
initiatives have grown out of working groups, which have a 
structure for joint multicenter research and development 
projects. The working groups have facilitated substantial 
progress within e.g. imaging, target definition and treatment 
planning, and this has become the basis of novel guidelines 
such as the GEC ESTRO recommendations for cervix, 
prostate, breast, as well as head & neck brachytherapy. The 
most recent example is the guideline on target definition for 
accelerated partial breast irradiation (APBI) which was 
published by the GEC ESTRO breast working group (Strnad et 
al) in June 2015 in Radiotherapy & Oncology. In parallel, the 
GEC ESTRO breast working group has been carrying out a 
randomized study on APBI, and this has further strengthened 
the impact of the guidelines. The clinical outcome of the 
study was published in Lancet in October 2015, and this is an 
excellent example of possible synergy between development 
of guidelines and related research activities. Other initiatives 
from GEC ESTRO include the current development of 
guidelines on bladder brachytherapy (Bradley Pieters), 
quality assurance of ultrasound in brachytherapy (Frank 
André-Siebert), as well as an update on head & neck 
brachytherapy (György Kovács). During the last decade there 
has been extensive collaboration between ESTRO (in 
particular the BRAPHYQS working group and AAPM therapy 
group on joint physics recommendations and guidelines. The 
underlying idea is that the gathering of experts from 
different continents improves quality, and that 
geographically broader views improve the global applicability 
of guidelines. Examples of recently published joint GEC 
ESTRO/AAPM guidelines are guidelines for uncertainty 
analysis (Christian Kirisits), robotic brachytherapy (Tarun 
Podder), and the report on High Energy Brachytherapy 
Dosimetry (Jose Perez-Calatayud). Uncertainty analysis is an 
example of a research field which has been well developed in 
external beam radiotherapy, but was less developed in 
brachytherapy for many years – mainly due to the fact that 
3D imaging was introduced later in brachytherapy than in 
external beam radiotherapy. The guidelines for uncertainty 
analysis (Kirisits) showed therefore big impact on the field, 
and there is altogether now an increasing attention towards 
quantification of uncertainties in brachytherapy and 
considerations about how to improve clinical outcome by 
decreasing uncertainties. Joint GEC ESTRO/AAPM 
recommendations currently in progress are: TG - 167 
Recommendations by the AAPM and GEC-ESTRO on the use of 
new or innovative brachytherapy sources, devices, 
applicators, or applications: Report of Task Group 167 
(Ravinder Nath) and Supplement 2 to the 2004 update of the 
AAPM Task Group No. 43 Report (Mark Rivard). ESTRO physics 
has published several booklets on QA guidelines. Non-
brachytherapy physics guidelines in progress are Quality 
Management in RT: The use of industry Quality Tools (Crister 
Ceberg), QA guidelines for CBCT developed together with 
EFOMP (Alberto Torressin), and also guidelines on Technology 
for Precision Small Animal Radiotherapy Research (Frank 
Verhaegen and Dietmar Georg). ESTRO physics committee 
and AAPM are currently working on a memorandum of 
understanding (MoU) with the aim of increasing scientific 
